• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

目前 IIIA(N2)期非小细胞肺癌的治疗管理:围手术期免疫治疗和酪氨酸激酶抑制剂的作用。

Current Management of Stage IIIA (N2) Non-Small-Cell Lung Cancer: Role of Perioperative Immunotherapy, and Tyrosine Kinase Inhibitors.

机构信息

Section of Thoracic Surgery, Department of Surgery, University of Chicago Medicine, Room S-546/MC 5047, 5841 South Maryland Avenue, Chicago, IL 60637, USA.

Section of Thoracic Surgery, Department of Surgery, University of Chicago Medicine, Room S-546/MC 5047, 5841 South Maryland Avenue, Chicago, IL 60637, USA.

出版信息

Thorac Surg Clin. 2023 May;33(2):189-196. doi: 10.1016/j.thorsurg.2023.01.006. Epub 2023 Feb 26.

DOI:10.1016/j.thorsurg.2023.01.006
PMID:37045488
Abstract

There have been numerous recent advances in the treatmetn of stage IIIA non-small cell lung cancer. The most significant involve the addition of targeted therapies adn immune checkpoint inhibitors into perioperative care. These exciting advances are improving survival in this challenging patient population, but some-decade old controveries around the definition of resectability, prognositic importance of tumor response to induction therapy, and the role of pneumonectomy persist.

摘要

近年来,III 期非小细胞肺癌的治疗取得了众多进展。最显著的进展涉及将靶向治疗和免疫检查点抑制剂纳入围手术期治疗。这些令人兴奋的进展改善了这一具有挑战性的患者群体的生存情况,但有关可切除性的定义、诱导治疗后肿瘤反应的预后重要性以及肺切除术的作用等数十年的争议仍然存在。

相似文献

1
Current Management of Stage IIIA (N2) Non-Small-Cell Lung Cancer: Role of Perioperative Immunotherapy, and Tyrosine Kinase Inhibitors.目前 IIIA(N2)期非小细胞肺癌的治疗管理:围手术期免疫治疗和酪氨酸激酶抑制剂的作用。
Thorac Surg Clin. 2023 May;33(2):189-196. doi: 10.1016/j.thorsurg.2023.01.006. Epub 2023 Feb 26.
2
Surgery as a Component of Multimodality Care for Known Stage IIIA-N2 Non-small Cell Lung Cancer.手术作为已知 IIIA-N2 期非小细胞肺癌多模态治疗的一部分。
Semin Respir Crit Care Med. 2020 Jun;41(3):346-353. doi: 10.1055/s-0039-1698436. Epub 2020 May 25.
3
A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209).一项针对IIIA期N2非小细胞肺癌患者比较诱导化疗后手术与单纯手术的随机试验(JCOG 9209)。
J Thorac Cardiovasc Surg. 2003 Feb;125(2):254-60. doi: 10.1067/mtc.2003.15.
4
Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).诱导化疗和同期放化疗后可切除 IIIA(N2)和部分 IIIB 期非小细胞肺癌患者的手术与根治性同期放化疗增敏的 III 期研究(ESPATUE)
J Clin Oncol. 2015 Dec 10;33(35):4194-201. doi: 10.1200/JCO.2015.62.6812. Epub 2015 Nov 2.
5
Role of surgery in N2 NSCLC: pros.手术在N2期非小细胞肺癌中的作用:优势
Jpn J Clin Oncol. 2016 Dec;46(12):1168-1173. doi: 10.1093/jjco/hyw125. Epub 2016 Sep 21.
6
Management of stage IIIA non-small cell lung cancer by thoracic surgeons in North America.北美胸外科医生治疗 IIIA 期非小细胞肺癌。
Ann Thorac Surg. 2012 Sep;94(3):922-6; discussion 926-8. doi: 10.1016/j.athoracsur.2012.04.087. Epub 2012 Jun 27.
7
Treatment of stage IIIA non-small cell lung cancer.IIIA期非小细胞肺癌的治疗。
Chest. 2003 Jan;123(1 Suppl):202S-220S. doi: 10.1378/chest.123.1_suppl.202s.
8
Scalpels, beams, drugs, and dreams: challenges of stage IIIA-N2 non-small-cell lung cancer.手术刀、射线、药物与梦想:IIIA-N2期非小细胞肺癌的挑战
J Natl Cancer Inst. 2007 Mar 21;99(6):415-8. doi: 10.1093/jnci/djk107.
9
Management of Stage IIIA (N2) Non-Small Cell Lung Cancer.ⅢA期(N2)非小细胞肺癌的管理
Thorac Surg Clin. 2016 Aug;26(3):271-85. doi: 10.1016/j.thorsurg.2016.04.001.
10
Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.对于ⅢA期(N2)非小细胞肺癌患者,在手术切除前接受新辅助化疗和/或放疗是否有生存获益:一项系统评价和Meta分析
Medicine (Baltimore). 2015 Jun;94(23):e879. doi: 10.1097/MD.0000000000000879.

引用本文的文献

1
Network meta-analysis on the efficacy and safety of management for resectable stage IIIA-N2 non-small cell lung cancer.可切除 IIIA-N2 期非小细胞肺癌的疗效和安全性的网状荟萃分析。
BMC Cancer. 2024 Oct 16;24(1):1286. doi: 10.1186/s12885-024-13047-2.